nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrimeprazine—HTR2C—Sorafenib—kidney cancer	0.0863	0.197	CbGbCtD
Methotrimeprazine—CYP2D6—Temsirolimus—kidney cancer	0.0849	0.193	CbGbCtD
Methotrimeprazine—CYP1A2—Pazopanib—kidney cancer	0.0541	0.123	CbGbCtD
Methotrimeprazine—CYP2D6—Pazopanib—kidney cancer	0.0446	0.102	CbGbCtD
Methotrimeprazine—CYP1A2—Erlotinib—kidney cancer	0.0386	0.088	CbGbCtD
Methotrimeprazine—CYP2D6—Erlotinib—kidney cancer	0.0318	0.0725	CbGbCtD
Methotrimeprazine—CYP1A2—Sorafenib—kidney cancer	0.0314	0.0716	CbGbCtD
Methotrimeprazine—Necrotizing enterocolitis—Paclitaxel—kidney cancer	0.0313	0.0924	CcSEcCtD
Methotrimeprazine—Necrotising enterocolitis neonatal—Paclitaxel—kidney cancer	0.0313	0.0924	CcSEcCtD
Methotrimeprazine—CYP2D6—Sorafenib—kidney cancer	0.0259	0.059	CbGbCtD
Methotrimeprazine—Necrotising enterocolitis neonatal—Capecitabine—kidney cancer	0.0257	0.0758	CcSEcCtD
Methotrimeprazine—Necrotizing enterocolitis—Capecitabine—kidney cancer	0.0257	0.0758	CcSEcCtD
Methotrimeprazine—Necrotising colitis—Paclitaxel—kidney cancer	0.0256	0.0755	CcSEcCtD
Methotrimeprazine—CYP2D6—Vinblastine—kidney cancer	0.0255	0.0582	CbGbCtD
Methotrimeprazine—CHRM3—ureter—kidney cancer	0.0217	0.302	CbGeAlD
Methotrimeprazine—Necrotising colitis—Capecitabine—kidney cancer	0.021	0.062	CcSEcCtD
Methotrimeprazine—Sudden death, cause unknown—Capecitabine—kidney cancer	0.0179	0.0528	CcSEcCtD
Methotrimeprazine—CYP2D6—Doxorubicin—kidney cancer	0.0157	0.0358	CbGbCtD
Methotrimeprazine—Necrotising colitis—Doxorubicin—kidney cancer	0.0135	0.04	CcSEcCtD
Methotrimeprazine—Sudden death—Everolimus—kidney cancer	0.0103	0.0303	CcSEcCtD
Methotrimeprazine—Sudden death—Sunitinib—kidney cancer	0.00858	0.0253	CcSEcCtD
Methotrimeprazine—Drug interaction—Erlotinib—kidney cancer	0.00547	0.0161	CcSEcCtD
Methotrimeprazine—CYP1A2—urine—kidney cancer	0.00536	0.0745	CbGeAlD
Methotrimeprazine—Hepatocellular injury—Everolimus—kidney cancer	0.00526	0.0155	CcSEcCtD
Methotrimeprazine—Hepatocellular injury—Erlotinib—kidney cancer	0.00507	0.015	CcSEcCtD
Methotrimeprazine—Drug interaction—Sorafenib—kidney cancer	0.00492	0.0145	CcSEcCtD
Methotrimeprazine—CYP2E1—urine—kidney cancer	0.00482	0.067	CbGeAlD
Methotrimeprazine—Sudden death—Capecitabine—kidney cancer	0.00473	0.014	CcSEcCtD
Methotrimeprazine—HTR2A—urine—kidney cancer	0.00419	0.0582	CbGeAlD
Methotrimeprazine—Drug interaction—Vincristine—kidney cancer	0.004	0.0118	CcSEcCtD
Methotrimeprazine—CYP2D6—urine—kidney cancer	0.00382	0.053	CbGeAlD
Methotrimeprazine—Photosensitivity reaction—Pazopanib—kidney cancer	0.00381	0.0113	CcSEcCtD
Methotrimeprazine—Drug interaction—Gemcitabine—kidney cancer	0.0038	0.0112	CcSEcCtD
Methotrimeprazine—Jaundice—Pazopanib—kidney cancer	0.00363	0.0107	CcSEcCtD
Methotrimeprazine—Urinary retention—Everolimus—kidney cancer	0.00363	0.0107	CcSEcCtD
Methotrimeprazine—Drug interaction—Paclitaxel—kidney cancer	0.00318	0.00939	CcSEcCtD
Methotrimeprazine—Dimetacrine—ACHE—kidney cancer	0.00292	0.349	CrCbGaD
Methotrimeprazine—Jaundice—Everolimus—kidney cancer	0.00287	0.00846	CcSEcCtD
Methotrimeprazine—ADRA1B—renal system—kidney cancer	0.00282	0.0392	CbGeAlD
Methotrimeprazine—Agranulocytosis—Vinblastine—kidney cancer	0.00275	0.00813	CcSEcCtD
Methotrimeprazine—ADRA1B—kidney—kidney cancer	0.00273	0.0379	CbGeAlD
Methotrimeprazine—Urinary retention—Vincristine—kidney cancer	0.00256	0.00757	CcSEcCtD
Methotrimeprazine—Jaundice—Sorafenib—kidney cancer	0.00249	0.00735	CcSEcCtD
Methotrimeprazine—Somnolence—Temsirolimus—kidney cancer	0.00224	0.00662	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Dactinomycin—kidney cancer	0.00217	0.00641	CcSEcCtD
Methotrimeprazine—Constipation—Temsirolimus—kidney cancer	0.00216	0.00636	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Vincristine—kidney cancer	0.00213	0.00628	CcSEcCtD
Methotrimeprazine—Somnolence—Pazopanib—kidney cancer	0.00211	0.00623	CcSEcCtD
Methotrimeprazine—Photosensitivity—Capecitabine—kidney cancer	0.002	0.00591	CcSEcCtD
Methotrimeprazine—Orthostatic hypotension—Paclitaxel—kidney cancer	0.00196	0.00577	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Temsirolimus—kidney cancer	0.00186	0.00548	CcSEcCtD
Methotrimeprazine—Liver injury—Doxorubicin—kidney cancer	0.00185	0.00547	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Gemcitabine—kidney cancer	0.00184	0.00543	CcSEcCtD
Methotrimeprazine—Tachycardia—Everolimus—kidney cancer	0.00183	0.0054	CcSEcCtD
Methotrimeprazine—CHRM3—renal system—kidney cancer	0.00173	0.024	CbGeAlD
Methotrimeprazine—Photosensitivity reaction—Paclitaxel—kidney cancer	0.00169	0.00499	CcSEcCtD
Methotrimeprazine—Weight increased—Paclitaxel—kidney cancer	0.00168	0.00497	CcSEcCtD
Methotrimeprazine—CHRM3—kidney—kidney cancer	0.00167	0.0232	CbGeAlD
Methotrimeprazine—Urinary retention—Capecitabine—kidney cancer	0.00167	0.00493	CcSEcCtD
Methotrimeprazine—Somnolence—Everolimus—kidney cancer	0.00167	0.00492	CcSEcCtD
Methotrimeprazine—ADRA2C—nephron tubule—kidney cancer	0.00166	0.0231	CbGeAlD
Methotrimeprazine—Constipation—Vinblastine—kidney cancer	0.00161	0.00475	CcSEcCtD
Methotrimeprazine—Orthostatic hypotension—Capecitabine—kidney cancer	0.0016	0.00474	CcSEcCtD
Methotrimeprazine—Constipation—Everolimus—kidney cancer	0.0016	0.00473	CcSEcCtD
Methotrimeprazine—ADRA1A—renal system—kidney cancer	0.00159	0.022	CbGeAlD
Methotrimeprazine—Hepatocellular injury—Doxorubicin—kidney cancer	0.00156	0.00461	CcSEcCtD
Methotrimeprazine—Constipation—Erlotinib—kidney cancer	0.00155	0.00457	CcSEcCtD
Methotrimeprazine—ADRA2C—renal system—kidney cancer	0.00151	0.021	CbGeAlD
Methotrimeprazine—ADRA2C—kidney—kidney cancer	0.00146	0.0203	CbGeAlD
Methotrimeprazine—ADRA2C—cortex of kidney—kidney cancer	0.00142	0.0198	CbGeAlD
Methotrimeprazine—Constipation—Sorafenib—kidney cancer	0.00139	0.00411	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Vinblastine—kidney cancer	0.00139	0.00409	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Capecitabine—kidney cancer	0.00139	0.00409	CcSEcCtD
Methotrimeprazine—Weight increased—Capecitabine—kidney cancer	0.00138	0.00408	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Everolimus—kidney cancer	0.00138	0.00408	CcSEcCtD
Methotrimeprazine—ADRA2C—cardiac atrium—kidney cancer	0.00135	0.0188	CbGeAlD
Methotrimeprazine—Constipation—Sunitinib—kidney cancer	0.00134	0.00395	CcSEcCtD
Methotrimeprazine—Jaundice—Capecitabine—kidney cancer	0.00132	0.0039	CcSEcCtD
Methotrimeprazine—CYP1A2—renal system—kidney cancer	0.00131	0.0182	CbGeAlD
Methotrimeprazine—CYP2E1—nephron tubule—kidney cancer	0.0013	0.018	CbGeAlD
Methotrimeprazine—Photosensitivity—Doxorubicin—kidney cancer	0.00129	0.00381	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Capecitabine—kidney cancer	0.00126	0.00373	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Sorafenib—kidney cancer	0.0012	0.00354	CcSEcCtD
Methotrimeprazine—CYP2E1—renal system—kidney cancer	0.00118	0.0164	CbGeAlD
Methotrimeprazine—Hypersensitivity—Sunitinib—kidney cancer	0.00115	0.00341	CcSEcCtD
Methotrimeprazine—CYP2E1—kidney—kidney cancer	0.00114	0.0158	CbGeAlD
Methotrimeprazine—ADRA2A—cortex of kidney—kidney cancer	0.00114	0.0158	CbGeAlD
Methotrimeprazine—Constipation—Vincristine—kidney cancer	0.00113	0.00334	CcSEcCtD
Methotrimeprazine—Somnolence—Gemcitabine—kidney cancer	0.00112	0.0033	CcSEcCtD
Methotrimeprazine—CYP2E1—cortex of kidney—kidney cancer	0.00111	0.0154	CbGeAlD
Methotrimeprazine—Hypersensitivity—Dactinomycin—kidney cancer	0.00109	0.00323	CcSEcCtD
Methotrimeprazine—ADRA2A—gonad—kidney cancer	0.00108	0.015	CbGeAlD
Methotrimeprazine—ADRA2A—cardiac atrium—kidney cancer	0.00108	0.015	CbGeAlD
Methotrimeprazine—Constipation—Gemcitabine—kidney cancer	0.00107	0.00317	CcSEcCtD
Methotrimeprazine—Orthostatic hypotension—Doxorubicin—kidney cancer	0.00103	0.00305	CcSEcCtD
Methotrimeprazine—Tachycardia—Paclitaxel—kidney cancer	0.00103	0.00303	CcSEcCtD
Methotrimeprazine—HTR2A—renal system—kidney cancer	0.00103	0.0142	CbGeAlD
Methotrimeprazine—Ethopropazine—BCHE—kidney cancer	0.00102	0.122	CrCbGaD
Methotrimeprazine—HTR2A—kidney—kidney cancer	0.000992	0.0138	CbGeAlD
Methotrimeprazine—Hypersensitivity—Vincristine—kidney cancer	0.000976	0.00288	CcSEcCtD
Methotrimeprazine—Somnolence—Paclitaxel—kidney cancer	0.000935	0.00276	CcSEcCtD
Methotrimeprazine—CYP2D6—renal system—kidney cancer	0.000934	0.013	CbGeAlD
Methotrimeprazine—HTR2A—gonad—kidney cancer	0.00092	0.0128	CbGeAlD
Methotrimeprazine—CYP2D6—kidney—kidney cancer	0.000903	0.0125	CbGeAlD
Methotrimeprazine—Constipation—Paclitaxel—kidney cancer	0.0009	0.00266	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Doxorubicin—kidney cancer	0.000893	0.00264	CcSEcCtD
Methotrimeprazine—Weight increased—Doxorubicin—kidney cancer	0.000891	0.00263	CcSEcCtD
Methotrimeprazine—Drowsiness—Doxorubicin—kidney cancer	0.000873	0.00258	CcSEcCtD
Methotrimeprazine—Clomipramine—GSTP1—kidney cancer	0.000857	0.102	CrCbGaD
Methotrimeprazine—Jaundice—Doxorubicin—kidney cancer	0.000851	0.00251	CcSEcCtD
Methotrimeprazine—Tachycardia—Capecitabine—kidney cancer	0.000843	0.00249	CcSEcCtD
Methotrimeprazine—Triflupromazine—BCHE—kidney cancer	0.000836	0.0998	CrCbGaD
Methotrimeprazine—Agranulocytosis—Doxorubicin—kidney cancer	0.000814	0.0024	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Paclitaxel—kidney cancer	0.000775	0.00229	CcSEcCtD
Methotrimeprazine—Constipation—Capecitabine—kidney cancer	0.000738	0.00218	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Capecitabine—kidney cancer	0.000636	0.00188	CcSEcCtD
Methotrimeprazine—Tachycardia—Doxorubicin—kidney cancer	0.000543	0.0016	CcSEcCtD
Methotrimeprazine—Somnolence—Doxorubicin—kidney cancer	0.000495	0.00146	CcSEcCtD
Methotrimeprazine—Constipation—Doxorubicin—kidney cancer	0.000476	0.00141	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Doxorubicin—kidney cancer	0.00041	0.00121	CcSEcCtD
Methotrimeprazine—Chlorpromazine—BCHE—kidney cancer	0.000403	0.0481	CrCbGaD
Methotrimeprazine—Diltiazem—ABCB1—kidney cancer	0.000368	0.0439	CrCbGaD
Methotrimeprazine—Triflupromazine—ABCB1—kidney cancer	0.000328	0.0391	CrCbGaD
Methotrimeprazine—Fluphenazine—ABCB1—kidney cancer	0.000252	0.0301	CrCbGaD
Methotrimeprazine—Clomipramine—ABCB1—kidney cancer	0.00023	0.0275	CrCbGaD
Methotrimeprazine—Chlorprothixene—ABCB1—kidney cancer	0.000229	0.0274	CrCbGaD
Methotrimeprazine—Trimipramine—ABCB1—kidney cancer	0.000212	0.0253	CrCbGaD
Methotrimeprazine—Promethazine—ABCB1—kidney cancer	0.000204	0.0244	CrCbGaD
Methotrimeprazine—Trifluoperazine—ABCB1—kidney cancer	0.000201	0.024	CrCbGaD
Methotrimeprazine—Chlorpromazine—ABCB1—kidney cancer	0.000158	0.0189	CrCbGaD
Methotrimeprazine—Imipramine—ABCB1—kidney cancer	0.000157	0.0188	CrCbGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—CCND1—kidney cancer	1.05e-05	7.36e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—JUN—kidney cancer	1.04e-05	7.35e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—CTNNB1—kidney cancer	1.04e-05	7.29e-05	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—MYC—kidney cancer	1.03e-05	7.27e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—IL2—kidney cancer	1.03e-05	7.25e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—GSTM1—kidney cancer	1.03e-05	7.24e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—CDKN1B—kidney cancer	1.03e-05	7.21e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—VEGFA—kidney cancer	1.02e-05	7.21e-05	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—MAPK1—kidney cancer	1.02e-05	7.2e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling by GPCR—PIK3CA—kidney cancer	1.02e-05	7.19e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—MAPK3—kidney cancer	1.02e-05	7.15e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—RAF1—kidney cancer	1.02e-05	7.14e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—VEGFA—kidney cancer	1.01e-05	7.11e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—VEGFA—kidney cancer	1.01e-05	7.11e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—RELA—kidney cancer	1.01e-05	7.11e-05	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—MAPK1—kidney cancer	1.01e-05	7.11e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—PTEN—kidney cancer	1.01e-05	7.11e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—CDKN1B—kidney cancer	1.01e-05	7.1e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—GPCR downstream signaling—PIK3CA—kidney cancer	1.01e-05	7.09e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling by GPCR—PIK3CA—kidney cancer	1.01e-05	7.08e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—CCND1—kidney cancer	1.01e-05	7.07e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—ERBB2—kidney cancer	1e-05	7.06e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling by GPCR—PIK3CA—kidney cancer	1e-05	7.06e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—JUN—kidney cancer	1e-05	7.06e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—IL2—kidney cancer	1e-05	7.05e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling by GPCR—PIK3CA—kidney cancer	1e-05	7.04e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Metabolism—PTEN—kidney cancer	9.99e-06	7.03e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—RAF1—kidney cancer	9.99e-06	7.02e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling by GPCR—PIK3CA—kidney cancer	9.98e-06	7.02e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—RAF1—kidney cancer	9.97e-06	7.01e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling by GPCR—KRAS—kidney cancer	9.96e-06	7.01e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—CTNNB1—kidney cancer	9.96e-06	7e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—RELA—kidney cancer	9.94e-06	6.99e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—RAF1—kidney cancer	9.93e-06	6.99e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—RELA—kidney cancer	9.92e-06	6.98e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—MTOR—kidney cancer	9.91e-06	6.97e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—RAF1—kidney cancer	9.9e-06	6.96e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—MYC—kidney cancer	9.89e-06	6.96e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—RELA—kidney cancer	9.89e-06	6.96e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—ERBB2—kidney cancer	9.88e-06	6.95e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling by GPCR—PIK3CA—kidney cancer	9.88e-06	6.95e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—IL2—kidney cancer	9.87e-06	6.94e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—ERBB2—kidney cancer	9.86e-06	6.93e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—RELA—kidney cancer	9.86e-06	6.93e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling by GPCR—PIK3CA—kidney cancer	9.85e-06	6.93e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—ERBB2—kidney cancer	9.83e-06	6.91e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—RAF1—kidney cancer	9.81e-06	6.9e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—ERBB2—kidney cancer	9.8e-06	6.89e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—RAF1—kidney cancer	9.78e-06	6.88e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—CCND1—kidney cancer	9.78e-06	6.88e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—RELA—kidney cancer	9.76e-06	6.87e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—CYP1A1—kidney cancer	9.76e-06	6.86e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—JUN—kidney cancer	9.76e-06	6.86e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—MTOR—kidney cancer	9.75e-06	6.86e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—RELA—kidney cancer	9.74e-06	6.85e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—MTOR—kidney cancer	9.73e-06	6.84e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—PTEN—kidney cancer	9.7e-06	6.82e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—ERBB2—kidney cancer	9.7e-06	6.82e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—MTOR—kidney cancer	9.7e-06	6.82e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—MAPK3—kidney cancer	9.69e-06	6.82e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—CTNNB1—kidney cancer	9.68e-06	6.81e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—MAPK1—kidney cancer	9.68e-06	6.81e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—ERBB2—kidney cancer	9.68e-06	6.81e-05	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—KRAS—kidney cancer	9.68e-06	6.8e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—MTOR—kidney cancer	9.67e-06	6.8e-05	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—PTGS2—kidney cancer	9.65e-06	6.79e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—CCND1—kidney cancer	9.62e-06	6.77e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—JUN—kidney cancer	9.6e-06	6.75e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—MTOR—kidney cancer	9.57e-06	6.73e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—MAPK3—kidney cancer	9.56e-06	6.73e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—MAPK3—kidney cancer	9.56e-06	6.73e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—MTOR—kidney cancer	9.55e-06	6.72e-05	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—KRAS—kidney cancer	9.54e-06	6.71e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—CTNNB1—kidney cancer	9.53e-06	6.7e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—PTEN—kidney cancer	9.44e-06	6.64e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—MYC—kidney cancer	9.43e-06	6.63e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—MYC—kidney cancer	9.3e-06	6.54e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—MYC—kidney cancer	9.3e-06	6.54e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—CDKN1B—kidney cancer	9.3e-06	6.54e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—PTEN—kidney cancer	9.29e-06	6.53e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—MAPK1—kidney cancer	9.22e-06	6.49e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Metabolism—PTEN—kidney cancer	9.17e-06	6.45e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling by GPCR—PIK3CA—kidney cancer	9.16e-06	6.44e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—CDKN1B—kidney cancer	9.15e-06	6.44e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—KRAS—kidney cancer	9.14e-06	6.43e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—CDKN1B—kidney cancer	9.13e-06	6.42e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—VEGFA—kidney cancer	9.13e-06	6.42e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—CDKN1B—kidney cancer	9.1e-06	6.4e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—IL2—kidney cancer	9.1e-06	6.4e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—MAPK1—kidney cancer	9.1e-06	6.4e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—MAPK1—kidney cancer	9.1e-06	6.4e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—RAF1—kidney cancer	9.09e-06	6.39e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—CDKN1B—kidney cancer	9.07e-06	6.38e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—RELA—kidney cancer	9.05e-06	6.36e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—ERBB2—kidney cancer	8.99e-06	6.32e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—CDKN1B—kidney cancer	8.99e-06	6.32e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—CDKN1B—kidney cancer	8.96e-06	6.3e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—IL2—kidney cancer	8.96e-06	6.3e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—IL2—kidney cancer	8.94e-06	6.29e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—IL2—kidney cancer	8.91e-06	6.26e-05	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—PIK3CA—kidney cancer	8.89e-06	6.25e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—IL2—kidney cancer	8.88e-06	6.24e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—CCND1—kidney cancer	8.87e-06	6.24e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—MTOR—kidney cancer	8.87e-06	6.24e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—JUN—kidney cancer	8.85e-06	6.23e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—IL2—kidney cancer	8.79e-06	6.18e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—CTNNB1—kidney cancer	8.79e-06	6.18e-05	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—PIK3CA—kidney cancer	8.77e-06	6.17e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—IL2—kidney cancer	8.77e-06	6.17e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—VEGFA—kidney cancer	8.76e-06	6.16e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—CCND1—kidney cancer	8.73e-06	6.14e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—JUN—kidney cancer	8.71e-06	6.13e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—CCND1—kidney cancer	8.71e-06	6.13e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—KRAS—kidney cancer	8.71e-06	6.13e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—JUN—kidney cancer	8.69e-06	6.11e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—CCND1—kidney cancer	8.68e-06	6.11e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—JUN—kidney cancer	8.67e-06	6.09e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—CCND1—kidney cancer	8.66e-06	6.09e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—CTNNB1—kidney cancer	8.65e-06	6.08e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—JUN—kidney cancer	8.64e-06	6.07e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—MAPK3—kidney cancer	8.63e-06	6.07e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—CTNNB1—kidney cancer	8.63e-06	6.07e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—CTNNB1—kidney cancer	8.6e-06	6.05e-05	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—TP53—kidney cancer	8.6e-06	6.05e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—KRAS—kidney cancer	8.59e-06	6.04e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—KRAS—kidney cancer	8.59e-06	6.04e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—POMC—kidney cancer	8.59e-06	6.04e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—CCND1—kidney cancer	8.57e-06	6.03e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—CTNNB1—kidney cancer	8.57e-06	6.03e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—PTEN—kidney cancer	8.56e-06	6.02e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—JUN—kidney cancer	8.55e-06	6.02e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—CCND1—kidney cancer	8.55e-06	6.01e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—JUN—kidney cancer	8.53e-06	6e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—VEGFA—kidney cancer	8.52e-06	6e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—CTNNB1—kidney cancer	8.49e-06	5.97e-05	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—TP53—kidney cancer	8.48e-06	5.97e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—CTNNB1—kidney cancer	8.47e-06	5.95e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—PTEN—kidney cancer	8.43e-06	5.93e-05	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—PTEN—kidney cancer	8.42e-06	5.92e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—PTEN—kidney cancer	8.41e-06	5.91e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—PIK3CA—kidney cancer	8.4e-06	5.91e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—MYC—kidney cancer	8.4e-06	5.91e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—VEGFA—kidney cancer	8.39e-06	5.9e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—PTEN—kidney cancer	8.38e-06	5.89e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—PTEN—kidney cancer	8.35e-06	5.88e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—CDKN1B—kidney cancer	8.33e-06	5.86e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—MAPK3—kidney cancer	8.29e-06	5.83e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—PTEN—kidney cancer	8.27e-06	5.82e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—PTEN—kidney cancer	8.25e-06	5.8e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—MAPK1—kidney cancer	8.21e-06	5.78e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—IL2—kidney cancer	8.15e-06	5.73e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—TP53—kidney cancer	8.12e-06	5.71e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—MAPK3—kidney cancer	8.06e-06	5.67e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—MYC—kidney cancer	8.06e-06	5.67e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	8.02e-06	5.64e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—PIK3CA—kidney cancer	8e-06	5.63e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Metabolism—PIK3CA—kidney cancer	7.96e-06	5.6e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—CCND1—kidney cancer	7.94e-06	5.59e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—MAPK3—kidney cancer	7.94e-06	5.58e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—JUN—kidney cancer	7.93e-06	5.57e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—PIK3CA—kidney cancer	7.9e-06	5.55e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—PIK3CA—kidney cancer	7.9e-06	5.55e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—MAPK1—kidney cancer	7.89e-06	5.55e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—CTNNB1—kidney cancer	7.87e-06	5.53e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—MYC—kidney cancer	7.84e-06	5.52e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—KRAS—kidney cancer	7.76e-06	5.46e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—TP53—kidney cancer	7.74e-06	5.44e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—VEGFA—kidney cancer	7.74e-06	5.44e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—MYC—kidney cancer	7.72e-06	5.43e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—MAPK1—kidney cancer	7.67e-06	5.4e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—PTEN—kidney cancer	7.67e-06	5.39e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—TP53—kidney cancer	7.64e-06	5.37e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—TP53—kidney cancer	7.64e-06	5.37e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—VEGFA—kidney cancer	7.61e-06	5.35e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—VEGFA—kidney cancer	7.59e-06	5.34e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—VEGFA—kidney cancer	7.57e-06	5.32e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—MAPK1—kidney cancer	7.55e-06	5.31e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—VEGFA—kidney cancer	7.55e-06	5.31e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—VEGFA—kidney cancer	7.47e-06	5.26e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—VEGFA—kidney cancer	7.45e-06	5.24e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—KRAS—kidney cancer	7.45e-06	5.24e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—MAPK3—kidney cancer	7.32e-06	5.15e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—POMC—kidney cancer	7.28e-06	5.12e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—KRAS—kidney cancer	7.25e-06	5.1e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—MAPK3—kidney cancer	7.2e-06	5.06e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—MAPK3—kidney cancer	7.18e-06	5.05e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—MAPK3—kidney cancer	7.16e-06	5.04e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—MAPK3—kidney cancer	7.14e-06	5.02e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—KRAS—kidney cancer	7.13e-06	5.02e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—PIK3CA—kidney cancer	7.13e-06	5.01e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—MYC—kidney cancer	7.12e-06	5.01e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—MAPK3—kidney cancer	7.07e-06	4.97e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—MAPK3—kidney cancer	7.05e-06	4.96e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Metabolism—PIK3CA—kidney cancer	7.05e-06	4.96e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—MYC—kidney cancer	7e-06	4.93e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—MYC—kidney cancer	6.99e-06	4.91e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—MYC—kidney cancer	6.97e-06	4.9e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—MAPK1—kidney cancer	6.96e-06	4.9e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—MYC—kidney cancer	6.94e-06	4.88e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—VEGFA—kidney cancer	6.92e-06	4.87e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—TP53—kidney cancer	6.9e-06	4.85e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—MYC—kidney cancer	6.88e-06	4.84e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—MYC—kidney cancer	6.86e-06	4.82e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—MAPK1—kidney cancer	6.85e-06	4.82e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—PTGS2—kidney cancer	6.85e-06	4.82e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—PIK3CA—kidney cancer	6.85e-06	4.81e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—MAPK1—kidney cancer	6.84e-06	4.81e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—MAPK1—kidney cancer	6.81e-06	4.79e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—MAPK1—kidney cancer	6.79e-06	4.78e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—MAPK1—kidney cancer	6.73e-06	4.73e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—MAPK1—kidney cancer	6.71e-06	4.72e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—PIK3CA—kidney cancer	6.66e-06	4.68e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—TP53—kidney cancer	6.62e-06	4.66e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—KRAS—kidney cancer	6.58e-06	4.62e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—PIK3CA—kidney cancer	6.55e-06	4.61e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—MAPK3—kidney cancer	6.55e-06	4.61e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—KRAS—kidney cancer	6.47e-06	4.55e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Metabolism—PIK3CA—kidney cancer	6.47e-06	4.55e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—KRAS—kidney cancer	6.46e-06	4.54e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—TP53—kidney cancer	6.44e-06	4.53e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—KRAS—kidney cancer	6.44e-06	4.53e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—KRAS—kidney cancer	6.42e-06	4.51e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—MYC—kidney cancer	6.37e-06	4.48e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—KRAS—kidney cancer	6.35e-06	4.47e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—TP53—kidney cancer	6.34e-06	4.46e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—KRAS—kidney cancer	6.34e-06	4.46e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—MAPK1—kidney cancer	6.23e-06	4.38e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—PIK3CA—kidney cancer	6.04e-06	4.25e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—PTEN—kidney cancer	5.97e-06	4.2e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—PIK3CA—kidney cancer	5.94e-06	4.18e-05	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—PIK3CA—kidney cancer	5.94e-06	4.18e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—PIK3CA—kidney cancer	5.93e-06	4.17e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—PIK3CA—kidney cancer	5.91e-06	4.16e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—PIK3CA—kidney cancer	5.89e-06	4.15e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—KRAS—kidney cancer	5.89e-06	4.14e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—TP53—kidney cancer	5.84e-06	4.11e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—PIK3CA—kidney cancer	5.84e-06	4.11e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—PIK3CA—kidney cancer	5.82e-06	4.09e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—PTGS2—kidney cancer	5.8e-06	4.08e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—TP53—kidney cancer	5.75e-06	4.04e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—TP53—kidney cancer	5.74e-06	4.04e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—TP53—kidney cancer	5.72e-06	4.02e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—TP53—kidney cancer	5.7e-06	4.01e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—TP53—kidney cancer	5.65e-06	3.97e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—TP53—kidney cancer	5.63e-06	3.96e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—PIK3CA—kidney cancer	5.41e-06	3.8e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—TP53—kidney cancer	5.23e-06	3.68e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—PTEN—kidney cancer	5.06e-06	3.56e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—PIK3CA—kidney cancer	4.21e-06	2.96e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—PIK3CA—kidney cancer	3.57e-06	2.51e-05	CbGpPWpGaD
